Rallybio Seeks Shareholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

Rallybio Corp is seeking shareholder approval for a reverse stock split, with a ratio between 1-for-5 and 1-for-20, to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting.

check_boxKey Events

• Reverse Stock Split Proposal

  Shareholders will vote on an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio ranging from 1-for-5 shares up to 1-for-20 shares, to be selected by the Board.

• Nasdaq Listing Compliance

  The primary purpose of the reverse stock split is to regain and maintain compliance with Nasdaq's $1.00 minimum bid price requirement to avoid delisting.

• Delisting Notice Received

  Rallybio received a delisting determination letter from Nasdaq on February 24, 2025, and has until February 23, 2026, to regain compliance.

• Increased Authorized Shares

  The reverse stock split will significantly increase the number of authorized but unissued shares, providing flexibility for general corporate purposes, including equity compensation plans.

auto_awesomeAnalysis

Rallybio Corp is proposing a reverse stock split to address its non-compliance with Nasdaq's minimum bid price requirement. The company received a delisting notice in February 2025 and is in its second 180-day compliance period, which expires in February 2026. While a reverse split can temporarily boost the share price to meet listing standards, it does not resolve the underlying operational or financial issues that led to the low stock price. The wide range of potential ratios (1-for-5 to 1-for-20) indicates the severity of the challenge. Investors should view this as a critical measure to maintain market access, but also as a strong signal of the company's distressed financial position and the potential for future dilution from the increased pool of authorized but unissued shares.